CDXSHealthcare · BiotechnologyThe 8 Wall Street analysts covering Codexis, Inc. hold a median 12-month price target of $5 — +309.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 29 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Codexis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Volatility (10): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CDXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +309.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $9.00 → $8.00 |
| 22 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | $11 |
| 22 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | $11 |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 4 Nov 2024 | Benchmark | Reiterates | Hold | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 29 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Aug 2024 | Benchmark | Downgrade | Hold | — |
| 9 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 May 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 3 May 2024 | Benchmark | Reiterates | Buy | — |
| 29 Feb 2024 | Benchmark | Upgrade | Buy | — |
| 7 Nov 2023 | Benchmark | Downgrade | Hold | — |
| 6 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 1 Sept 2023 | Benchmark | Reiterates | Buy | — |
| 14 Aug 2023 | Stifel | Maintains | Buy | — |
| 21 July 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 9 May 2023 | Benchmark | Maintains | Buy | — |
| 9 May 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CDXS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Codexis, Inc. returned −49.6% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 54% of US stocks
Cheaper than 27% of US stocks
Cheaper than 84% of US stocks
Higher than 23% of US stocks
Higher than 33% of US stocks
Higher than 88% of US stocks
Higher than 15% of US stocks
Higher than 12% of US stocks
Higher than 17% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Codexis, Inc. has a market value of $140.2M and an enterprise value of $157.8M.
Revenue in the twelve months to 30 June 2026: $77.7M. The latest quarter shrank 2.7% year on year.
Net income over the same four quarters: −$30.7M, a −39.6% net margin.
Diluted earnings per share, trailing twelve months: $−0.34.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Trailing P/E: −2.6×; forward P/E: −4.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Codexis, Inc. employs 146 people — $532K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Codexis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Codexis announced it will report third-quarter 2026 financial results on November 12, 2026, after the market closes.
Why it matters — CDXS watchers can note the scheduled date when the company is expected to release its quarterly results.
Codexis announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. The collaboration aims to utilize Codexis's enzymatic solutions for siRNA manufacturing.
Why it matters — The agreement could expand the application of Codexis's ECO Synthesis platform into the growing siRNA therapeutics space, potentially broadening its commercial opportunities.
Codexis announced it will attend the Cantor Global Healthcare Conference 2026, scheduled for September 9-11, 2026, in New York, New York. The company is a provider of enzymatic solutions for manufacturing complex therapeutics.
Why it matters — A CDXS watcher would care because the conference provides an opportunity for the company to present its enzymatic solutions to the healthcare investment community.
Codexis was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Why it matters — An upgrade to Buy suggests increased positive sentiment around Codexis's near-term earnings outlook, which could influence how investors view the stock.
Codexis, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational highlights for the quarter.
Why it matters — Earnings call transcripts provide CDXS watchers with direct insight into management's commentary on quarterly performance and strategic direction.
The 8 Wall Street analysts covering Codexis, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Codexis, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Codexis, Inc. 63 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, Codexis, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +309.8% from the last close, and Ticker Nerd's factor model ranks Codexis, Inc. 63 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Codexis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $11 over the next 12 months.
Codexis, Inc. returned -49.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Codexis to Report Third Quarter 2026 Financial Results on November 12". Codexis announced it will report third-quarter 2026 financial results on November 12, 2026, after the market closes.
Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications. Its portfolio includes enzyme-based solutions, screening kits, and process development support designed to improve efficiency in complex manufacturing workflows. The company serves customers across the pharmaceutical, industrial, food, agricultural, and specialty chemicals markets, where engineered enzymes can help enable more precise and scalable production processes. Codexis also works on next-generation biotherapeutic and oligonucleotide manufacturing platforms, reflecting its role as a specialized provider of tools and technologies for modern drug development and advanced biological manufacturing. Headquartered in Redwood City, California, Codexis Inc. operates as a platform-driven company within the broader life sciences and synthetic biology market.
CEO Dr. Alison Moore Ph.D. · 146 employees · United States · https://www.codexis.com
